Tafinlar Capsules 50mg

Tafinlar (dabrafenib mesylate) capsules, 50mg (YJ code: 4291046M1020, standard: 50mg 1 capsule), manufactured by Novartis Pharma, are a kinase inhibitor used to treat specific types of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer that have a BRAF V600 gene mutation. It can be used alone or in combination with trametinib to block the action of abnormal BRAF proteins and stop cancer cell growth.